Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engaging leadership and nurses' mental health in German acute care hospitals: the mediating role of job resources.

BMC nursing·2026
Same author

[Formation of disease- and needs-related homogeneous groups of insured persons - PopGrouper 1.0].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))·2026
Same author

Regional variation in healthcare utilization among patients with depression in Germany: a multilevel analysis with PopGrouper-based multimorbidity adjustment.

Research in health services & regions·2026
Same author

Cost-effectiveness of prehabilitation for elderly (pre-)frail patients prior to elective surgery compared to standard care - an economic evaluation from a societal perspective.

BMC medicine·2026
Same author

Metal concentration in biological samples of shipyard welders: a scoping review.

International journal of hygiene and environmental health·2026
Same author

West African Policy Dialogue-impulse for better data: progress towards better analytics and better decisions.

BMC proceedings·2026
Same journal

Variability in the prescription of drugs with uncertain effectiveness. The case of SYSADOA in the Basque Country.

GMS health technology assessment·2019
Same journal

Q-SEA - a tool for quality assessment of ethics analyses conducted as part of health technology assessments.

GMS health technology assessment·2017
Same journal

Effects of continuous and intermittent renal replacement therapies among adult patients with acute kidney injury.

GMS health technology assessment·2017
Same journal

Telemedicine: The legal framework (or the lack of it) in Europe.

GMS health technology assessment·2016
Same journal

Complex health care interventions: Characteristics relevant for ethical analysis in health technology assessment.

GMS health technology assessment·2016
Same journal

Electronic health records: Is it a risk worth taking in healthcare delivery?

GMS health technology assessment·2015
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Interferons and natalizumab for multiple sclerosis.

Christine Clar1, Marcial Velasco Garrido, Christian Gericke

  • 1Technische Universität Berlin, Berlin, Deutschland.

GMS Health Technology Assessment
|February 4, 2011
PubMed
Summary
This summary is machine-generated.

Beta-interferons and natalizumab offer benefits for multiple sclerosis (MS) by reducing disease progression and exacerbations. However, both treatments have significant side effects and long-term effectiveness remains unclear, necessitating further research.

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Related Experiment Videos

Last Updated: Jun 4, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic, disabling central nervous system inflammatory disease with substantial healthcare costs.
  • Effective treatment options are crucial for managing MS progression and exacerbations.

Purpose of the Study:

  • To systematically review the evidence on the effectiveness and costs of beta-interferons and natalizumab for multiple sclerosis treatment.
  • To evaluate outcomes including disease progression, exacerbations, and adverse effects.

Main Methods:

  • Systematic literature search of databases (MEDLINE, EMBASE, Cochrane Library, HTA-databases).
  • Inclusion of systematic reviews and randomized controlled trials (RCTs) with ≥1 year observation.
  • Assessment of study quality and systematic data summarization; inclusion of cost-effectiveness analyses.

Main Results:

  • Beta-interferons reduced conversion to definite MS and progression in relapsing-remitting MS; effects on secondary/primary progressive MS were limited.
  • Higher-dose interferon beta-1a and interferon beta-1b showed superiority over lower-dose interferon beta-1a in reducing exacerbations.
  • Natalizumab reduced progression and exacerbations in relapsing-remitting and some secondary progressive MS, but carries risks of progressive multifocal leukoencephalopathy (PML).
  • Beta-interferons have frequent adverse effects (injection site reactions, flu-like symptoms), leading to treatment discontinuation; neutralising antibodies may impact efficacy.
  • Cost-effectiveness analyses indicate high costs for moderate benefits with interferon therapy; long-term data for both treatments are lacking.

Conclusions:

  • Beta-interferons and natalizumab demonstrate efficacy in managing MS symptoms and progression, but with notable safety concerns and side effects.
  • Natalizumab's risk of PML raises significant patient safety issues.
  • Current evidence on long-term effectiveness is limited, and the cost-effectiveness of interferon therapy is high, requiring further investigation, particularly for specific healthcare systems.